Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic trip...
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
About this item
Full title
Author / Creator
Kim, Sung-Bae , Dent, Rebecca , Im, Seock-Ah , Espié, Marc , Blau, Sibel , Tan, Antoinette R , Isakoff, Steven J , Oliveira, Mafalda , Saura, Cristina , Wongchenko, Matthew J , Kapp, Amy V , Chan, Wai Y , Singel, Stina M , Maslyar, Daniel J , Baselga, José , Kim, Sung-Bae , Lee, Keun Seok , Im, Seock-Ah , Espié, Marc , Wang, Hwei-Chung , Blau, Sibel , Dent, Rebecca , Tan, Antoinette , Sohn, Joo Hyuk , De Laurentiis, Michelino , Estevez, Laura Garcia , Huang, Chiun-Sheng , Romieu, Gilles , Velez, Michel , Villanueva, Rafael , Conte, Pier Franco , Dakhil, Shaker , Debled, Marc , Martin, Antonio Gonzalez , Hurvitz, Sara , Kim, Jee Hyun , Levy, Christelle , Oliveira, Mafalda , Rovira, Pedro Sanchez , Seo, Jae Hong , Valero, Vicente , Vidal, Gregory , Wong, Andrea , Allison, Mary Ann K , Figlin, Robert , Chan, David , Chen, Shin-Cheh , Chen, Yen-Hsun , Cobleigh, Melody , De Braud, Filippo , Dirix, Luc , Hansen, Vincent , Bessard, Anne Hardy , Iannotti, Nicholas , Isakoff, Steven , Lawler, William , Montaño, Alvaro , Salkini, Mohamad , Seigel, Leonard and LOTUS investigators
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer.
In this randomised, placebo-controlled, double-blind, p...
Alternative Titles
Full title
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Dent, Rebecca
Im, Seock-Ah
Espié, Marc
Blau, Sibel
Tan, Antoinette R
Isakoff, Steven J
Oliveira, Mafalda
Saura, Cristina
Wongchenko, Matthew J
Kapp, Amy V
Chan, Wai Y
Singel, Stina M
Maslyar, Daniel J
Baselga, José
Kim, Sung-Bae
Lee, Keun Seok
Im, Seock-Ah
Espié, Marc
Wang, Hwei-Chung
Blau, Sibel
Dent, Rebecca
Tan, Antoinette
Sohn, Joo Hyuk
De Laurentiis, Michelino
Estevez, Laura Garcia
Huang, Chiun-Sheng
Romieu, Gilles
Velez, Michel
Villanueva, Rafael
Conte, Pier Franco
Dakhil, Shaker
Debled, Marc
Martin, Antonio Gonzalez
Hurvitz, Sara
Kim, Jee Hyun
Levy, Christelle
Oliveira, Mafalda
Rovira, Pedro Sanchez
Seo, Jae Hong
Valero, Vicente
Vidal, Gregory
Wong, Andrea
Allison, Mary Ann K
Figlin, Robert
Chan, David
Chen, Shin-Cheh
Chen, Yen-Hsun
Cobleigh, Melody
De Braud, Filippo
Dirix, Luc
Hansen, Vincent
Bessard, Anne Hardy
Iannotti, Nicholas
Isakoff, Steven
Lawler, William
Montaño, Alvaro
Salkini, Mohamad
Seigel, Leonard
LOTUS investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5626630
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5626630
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(17)30450-3
